WaferGen Bio-systems, Inc. (NASDAQ:WGBS) Announces Approval From Stockholders on Merger with Takara Bio, How Will the Market Respond?

Genomics technology company, WaferGen Bio-systems, Inc. (NASDAQ:WGBS), announces that its stockholders have approved a previously announced merger agreement with Takara Bio USA Holdings, Inc.

FREMONT, Calif., Nov. 15, 2016 /PRNewswire/ — WaferGen Bio-systems, Inc. (WGBS), a publicly held genomics technology company (“WaferGen”), today announced that its stockholders have approved the adoption of the previously announced merger agreement by and among WaferGen, Takara Bio USA Holdings, Inc. (“Takara Bio”) and certain other parties thereto.

“We are very pleased with the outcome of today’s vote and thank all of our stockholders for their support,” said Rollie Carlson, Ph.D., President and Chief Executive Officer of WaferGen. “We are confident that our merger with Takara Bio is the best outcome for WaferGen and our stockholders and look forward to closing the transaction in the first quarter of 2017.”

Pursuant to the merger agreement, upon completion of the contemplated merger, WaferGen will become a wholly owned subsidiary of Takara Bio and WaferGen’s outstanding equity securities will be automatically converted into the right to receive a cash payment, as more fully described in the proxy statement filed by WaferGen with the Securities and Exchange Commission on September 15, 2016.

The merger remains subject to customary closing conditions set forth in the merger agreement and is expected to close in the first quarter of 2017.

About WaferGen

WaferGen is a biotechnology company that offers innovative genomic technology solutions for single-cell analysis and clinical research. The ICELL8™ Single-Cell System is a first of its kind system that can isolate thousands of single cells and processes specific cells for analysis, including Next Generation Sequencing. The system has demonstrated unbiased isolation of single cells from solid tumors, brain cells, pulmonary airway cells, and multiple cell lines. The SmartChip™ platform can be used for profiling and validating molecular biomarkers, and can perform massively-parallel singleplex PCR for one-step target enrichment and library preparation for clinical NGS. The Apollo 324™ system can be used to process DNA and RNA from clinical samples to next generation sequencing ready libraries. These technologies offer a powerful set of tools for biological analysis at the molecular and single-cell level in the life sciences, pharmaceutical, and clinical laboratory industries.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections.  Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms.  Forward-looking statements in this press release may address the following subjects among others: statements regarding the anticipated closing of the Takara Bio merger agreement, sufficiency of our capital resources, expected operating losses, expected revenues, expected expenses, expected cash usage, our expectations regarding our development of future products including single cell analysis technologies and our expectations concerning our competitive position and business strategy.  Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q.  We urge you to consider those risks and uncertainties in evaluating our forward-looking statements.  We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made.  Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Original Source


WaferGen Bio-systems, Inc. (NASDAQ:WGBS) shares are trading +5.380% on the news and in the range of $0.880 – 0.950 during the current trading session.  When taking a look at which direction the stock might be headed, investors often look to brokerage analysts who cover the stock.  Sell-side research firms on Wall Street currently have a consensus one-year price target of $1.500 on the stock.  This is according to brokerage analysts polled by Thomson Reuters First Call.

Are Shares of WaferGen Bio-systems, Inc. (NASDAQ:WGBS) Ready to Explode?  Sign up to our Newsletter to be the First to Know 

Sign up to get our Free Penny Stock Picks Before the Street!

Sell-side analysts are projecting earnings per share of $-0.080 for the next fiscal quarter.  For the current year, analysts are predicting earnings of $-0.860 per share according to First Call.

In looking at where the stock is trading on a technical level, the stock is trading +10.364% away from its 50-day moving average of $0.816.  Based on the most recent available data, the equity is -32.761% off of its 52-week high of $1.340 and +98.022% away from its 52-week low which is $0.455.

Today, the stock opened at $0.944 and the last bid at the time of writing stood at $0.901.  During the session thus far, the equity dipped down to $0.880 and touched $0.950 as the high point.  WaferGen Bio-systems, Inc. (NASDAQ:WGBS) has a market cap of $17.05M and has seen an average daily volume of 210,723 over the past three months.

Sign Up to Receive Breaking Alerts on Stocks That Are Primed to Make a Run in the Bar Below. 

Sign up to get our Free Penny Stock Picks Before the Street!

Disclaimer: Nothing contained in this publication is intended to constitute legal, tax, securities, or investment advice, nor an opinion regarding the appropriateness of any investment, nor a solicitation of any type. The general information contained in this publication should not be acted upon without obtaining specific legal, tax, and investment advice from a licensed professional.

Related posts

Leave a Comment